BioCentury on BioBusiness,
Smarting from Avastin in breast cancer, ODAC snubs AZ's olaparib in ovarian
Applying Avastin's lessons
Monday, June 30, 2014
With the memory of the 2011 withdrawal of Avastin
bevacizumab in breast cancer still fresh in their minds, members of FDA's Oncologic Drugs Advisory Committee
recommended against accelerated approval for olaparib from AstraZeneca plc
for ovarian cancer. Concerns about the validity and clinical significance of
the PFS data led the panel to conclude it could not put the therapy's risks in
On June 25,
ODAC voted 11-2 against recommending accelerated approval of olaparib as a
maintenance therapy for women with platinum-sensitive ovarian cancer.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]